125 related articles for article (PubMed ID: 15531713)
1. How thyroid tumors start and why it matters: kinase mutants as targets for solid cancer pharmacotherapy.
Fagin JA
J Endocrinol; 2004 Nov; 183(2):249-56. PubMed ID: 15531713
[TBL] [Abstract][Full Text] [Related]
2. New molecular targeted therapies in thyroid cancer.
Milano A; Chiofalo MG; Basile M; Salzano de Luna A; Pezzullo L; Caponigro F
Anticancer Drugs; 2006 Sep; 17(8):869-79. PubMed ID: 16940797
[TBL] [Abstract][Full Text] [Related]
3. The oncogenic activity of RET point mutants for follicular thyroid cells may account for the occurrence of papillary thyroid carcinoma in patients affected by familial medullary thyroid carcinoma.
Melillo RM; Cirafici AM; De Falco V; Bellantoni M; Chiappetta G; Fusco A; Carlomagno F; Picascia A; Tramontano D; Tallini G; Santoro M
Am J Pathol; 2004 Aug; 165(2):511-21. PubMed ID: 15277225
[TBL] [Abstract][Full Text] [Related]
4. Novel treatment of medullary thyroid cancer.
Sugawara M; Geffner DL; Martinez D; Hershman JM
Curr Opin Endocrinol Diabetes Obes; 2009 Oct; 16(5):367-72. PubMed ID: 19633548
[TBL] [Abstract][Full Text] [Related]
5. Targeted therapeutic approach for an anaplastic thyroid cancer in vitro and in vivo.
Stenner F; Liewen H; Zweifel M; Weber A; Tchinda J; Bode B; Samaras P; Bauer S; Knuth A; Renner C
Cancer Sci; 2008 Sep; 99(9):1847-52. PubMed ID: 18616678
[TBL] [Abstract][Full Text] [Related]
6. Targeting RET for thyroid cancer therapy.
Lanzi C; Cassinelli G; Nicolini V; Zunino F
Biochem Pharmacol; 2009 Feb; 77(3):297-309. PubMed ID: 19028457
[TBL] [Abstract][Full Text] [Related]
7. Role of BRAF in thyroid oncogenesis.
Caronia LM; Phay JE; Shah MH
Clin Cancer Res; 2011 Dec; 17(24):7511-7. PubMed ID: 21900390
[TBL] [Abstract][Full Text] [Related]
8. Clinical implications of BRAF mutation in thyroid carcinoma.
Puxeddu E; Durante C; Avenia N; Filetti S; Russo D
Trends Endocrinol Metab; 2008; 19(4):138-45. PubMed ID: 18337114
[TBL] [Abstract][Full Text] [Related]
9. New insights in thyroid follicular cell biology and its impact in thyroid cancer therapy.
Riesco-Eizaguirre G; Santisteban P
Endocr Relat Cancer; 2007 Dec; 14(4):957-77. PubMed ID: 18045949
[TBL] [Abstract][Full Text] [Related]
10. Apoptotic cell death induction and angiogenesis inhibition in large established medullary thyroid carcinoma xenografts by Ret inhibitor RPI-1.
Petrangolini G; Cuccuru G; Lanzi C; Tortoreto M; Belluco S; Pratesi G; Cassinelli G; Zunino F
Biochem Pharmacol; 2006 Aug; 72(4):405-14. PubMed ID: 16756963
[TBL] [Abstract][Full Text] [Related]
11. Transient partial response to sorafenib treatment in an adolescent patient with MEN2B syndrome and end-stage medullary thyroid carcinoma.
Aller S; Popescu A; Rao S; Morgan E; Gosiengfiao Y
Pediatr Blood Cancer; 2012 Jan; 58(1):98-100. PubMed ID: 21721105
[TBL] [Abstract][Full Text] [Related]
12. How molecular pathology is changing and will change the therapeutics of patients with follicular cell-derived thyroid cancer.
Couto JP; Prazeres H; Castro P; Lima J; Máximo V; Soares P; Sobrinho-Simões M
J Clin Pathol; 2009 May; 62(5):414-21. PubMed ID: 19147628
[TBL] [Abstract][Full Text] [Related]
13. [Diagnostic molecular biology in solid tumors--thyroid gland].
Faksvåg Haugen DR; Varhaug JE; Akslen LA; Lillehaug JR
Tidsskr Nor Laegeforen; 1998 May; 118(14):2199-203. PubMed ID: 9656818
[TBL] [Abstract][Full Text] [Related]
14. Cancer Drug Development: New Targets for Cancer Treatment.
Curt GA
Oncologist; 1996; 1(3):II-III. PubMed ID: 10387987
[TBL] [Abstract][Full Text] [Related]
15. Targeted therapy in radioiodine refractory thyroid cancer.
Pacini F; Brilli L; Marchisotta S
Q J Nucl Med Mol Imaging; 2009 Oct; 53(5):520-5. PubMed ID: 19910905
[TBL] [Abstract][Full Text] [Related]
16. BAY 43-9006 inhibition of oncogenic RET mutants.
Carlomagno F; Anaganti S; Guida T; Salvatore G; Troncone G; Wilhelm SM; Santoro M
J Natl Cancer Inst; 2006 Mar; 98(5):326-34. PubMed ID: 16507829
[TBL] [Abstract][Full Text] [Related]
17. Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway.
Gollob JA; Wilhelm S; Carter C; Kelley SL
Semin Oncol; 2006 Aug; 33(4):392-406. PubMed ID: 16890795
[TBL] [Abstract][Full Text] [Related]
18. Novel chemotherapy options for advanced thyroid tumors: small molecules offer great hope.
Deshpande HA; Gettinger SN; Sosa JA
Curr Opin Oncol; 2008 Jan; 20(1):19-24. PubMed ID: 18043252
[TBL] [Abstract][Full Text] [Related]
19. External beam radiation therapy for thyroid cancer.
Brierley JD; Tsang RW
Endocrinol Metab Clin North Am; 2008 Jun; 37(2):497-509, xi. PubMed ID: 18502339
[TBL] [Abstract][Full Text] [Related]
20. [Genetic causes of the thyroid carcinomas].
Jindrichová S; Vlcek P; Bendlová B
Cas Lek Cesk; 2004; 143(10):664-8. PubMed ID: 15584614
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
